

## REFERENCES

- Malaria Control Program in Thailand. Ministry of Public Health 2003;
- Adak T, Sharma VP and Orlov VS. Studies on the *Plasmodium vivax* relapse pattern in Delhi, India. The American journal of tropical medicine and hygiene 1998; 59: 175-9.
- Ahlm C, Wistrom J and Carlsson H. Chloroquine-Resistant *Plasmodium vivax* Malaria in Borneo. J Travel Med 1996; 3: 124.
- Alifrangis M, Enosse S, Khalil IF, *et al.* Prediction of *Plasmodium falciparum* resistance to sulfadoxine/pyrimethamine *in vivo* by mutations in the dihydrofolate reductase and dihydropteroate synthetase genes: a comparative study between sites of differing endemicity. The American journal of tropical medicine and hygiene 2003; 69: 601-6.
- Baird JK, Basri H, Purnomo, *et al.* Resistance to chloroquine by *Plasmodium vivax* in Irian Jaya, Indonesia. The American journal of tropical medicine and hygiene 1991; 44: 547-52.
- Baird JK, Wiady I, Fryauff DJ, *et al.* *In vivo* resistance to chloroquine by *Plasmodium vivax* and *Plasmodium falciparum* at Nabire, Irian Jaya, Indonesia. The American journal of tropical medicine and hygiene 1997; 56: 627-31.
- Barnwell JW and Galinski MR. *Plasmodium vivax*: a glimpse into the unique and shared biology of the merozoite. Annals of tropical medicine and parasitology 1995; 89: 113-20.
- Basco LK, Eldin de Pecoulas P, Wilson CM, Le Bras J and Mazabraud A. Point mutations in the dihydrofolate reductase-thymidylate synthase gene and pyrimethamine and cycloguanil resistance in *Plasmodium falciparum*. Molecular and biochemical parasitology 1995; 69: 135-8.
- Basco LK and Ringwald P. Molecular epidemiology of malaria in Yaounde, Cameroon. VI. Sequence variations in the *Plasmodium falciparum* dihydrofolate reductase-

- thymidylate synthase gene and *in vitro* resistance to pyrimethamine and cycloguanil. *The American journal of tropical medicine and hygiene* 2000; 62: 271-6.
- Basco LK, Tahar R and Ringwald P. Molecular basis of *in vivo* resistance to sulfadoxine-pyrimethamine in African adult patients infected with *Plasmodium falciparum* malaria parasites. *Antimicrobial agents and chemotherapy* 1998; 42: 1811-4.
- Breman JG. The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. *The American journal of tropical medicine and hygiene* 2001; 64: 1-11.
- Brockelman CR, Tan-Ariya P and Bunnag D. Development of *in vitro* microtest for the assessment of *Plasmodium vivax* sensitivity to chloroquine. *The Southeast Asian journal of tropical medicine and public health* 1989; 20: 41-7.
- Bruce MC, Galinski MR, Barnwell JW, *et al.* Genetic diversity and dynamics of *Plasmodium falciparum* and *P. vivax* populations in multiply infected children with asymptomatic malaria infections in Papua New Guinea. *Parasitology* 2000; 121 ( Pt 3): 257-72.
- Bruce MC, Galinski MR, Barnwell JW, Snounou G and Day KP. Polymorphism at the merozoite surface protein-3 alpha locus of *Plasmodium vivax*: global and local diversity. *The American journal of tropical medicine and hygiene* 1999; 61: 518-25.
- Bzik DJ, Li WB, Horii T and Inselburg J. Molecular cloning and sequence analysis of the *Plasmodium falciparum* dihydrofolate reductase-thymidylate synthase gene. *Proceedings of the National Academy of Sciences of the United States of America* 1987; 84: 8360-4.
- Carter R. Speculations on the origins of *Plasmodium vivax* malaria. *Trends in parasitology* 2003; 19: 214-9.
- Carter R and Mendis KN. Evolutionary and historical aspects of the burden of malaria. *Clinical microbiology reviews* 2002; 15: 564-94.
- Chai JY. Re-emerging *Plasmodium vivax* malaria in the Republic of Korea. *The Korean journal of parasitology* 1999; 37: 129-43.

- Chareonviriyaphap T, Bangs MJ and Ratanatham S. Status of malaria in Thailand. The Southeast Asian journal of tropical medicine and public health 2000; 31: 225-37.
- Chotivanich K, Udomsangpetch R, Chierakul W, *et al.* *In vitro* efficacy of antimalarial drugs against *Plasmodium vivax* on the western border of Thailand. The American journal of tropical medicine and hygiene 2004; 70: 395-7.
- Congpuong K, Na-Bangchang K, Thimasarn K, Tasanor U and Wernsdorfer WH. Sensitivity of *Plasmodium vivax* to chloroquine in Sa Kaeo Province, Thailand. Acta tropica 2002; 83: 117-21.
- Cowman AF, Morry MJ, Biggs BA, Cross GA and Foote SJ. Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of *Plasmodium falciparum*. Proceedings of the National Academy of Sciences of the United States of America 1988; 85: 9109-13.
- Cui L, Mascorro CN, Fan Q, *et al.* Genetic diversity and multiple infections of *Plasmodium vivax* malaria in Western Thailand. The American journal of tropical medicine and hygiene 2003; 68: 613-9.
- de Pecoulas P, Basco LK, Tahar R, Ouatas T and Mazabraud A. Analysis of the *Plasmodium vivax* dihydrofolate reductase-thymidylate synthase gene sequence. Gene 1998a; 211: 177-85.
- de Pecoulas PE, Basco LK, Le Bras J and Mazabraud A. Association between antifol resistance *in vitro* and DHFR gene point mutation in *Plasmodium falciparum* isolates. Transactions of the Royal Society of Tropical Medicine and Hygiene 1996; 90: 181-2.
- de Pecoulas PE, Tahar R, Ouatas T, Mazabraud A and Basco LK. Sequence variations in the *Plasmodium vivax* dihydrofolate reductase-thymidylate synthase gene and their relationship with pyrimethamine resistance. Molecular and biochemical parasitology 1998b; 92: 265-73.
- de Pecoulas PE, Tahar R, Yi P, Thai KH and Basco LK. Genetic variation of the dihydrofolate reductase gene in *Plasmodium vivax* in Snoul, northeastern Cambodia. Acta tropica 2004; 92: 1-6.

- Desjardins RE, Canfield CJ, Haynes JD and Chulay JD. Quantitative assessment of antimalarial activity *in vitro* by a semiautomated microdilution technique. *Antimicrobial agents and chemotherapy* 1979; 16: 710-8.
- Djimde A, Doumbo OK, Cortese JF, *et al.* A molecular marker for chloroquine-resistant *falciparum* malaria. *The New England journal of medicine* 2001; 344: 257-63.
- Dua VK, Kar PK and Sharma VP. Chloroquine resistant *Plasmodium vivax* malaria in India. *Trop Med Int Health* 1996; 1: 816-9.
- Duraisingh MT, Curtis J and Warhurst DC. *Plasmodium falciparum*: detection of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes by PCR and restriction digestion. *Experimental parasitology* 1998; 89: 1-8.
- Escalante AA, Cornejo OE, Freeland DE, *et al.* A monkey's tale: the origin of *Plasmodium vivax* as a human malaria parasite. *Proceedings of the National Academy of Sciences of the United States of America* 2005; 102: 1980-5.
- Escalante AA, Lal AA and Ayala FJ. Genetic polymorphism and natural selection in the malaria parasite *Plasmodium falciparum*. *Genetics* 1998; 149: 189-202.
- Ferone R. Folate metabolism in malaria. *Bulletin of the World Health Organization* 1977; 55: 291-8.
- Ferone R, Burchall JJ and Hitchings GH. *Plasmodium berghei* dihydrofolate reductase. Isolation, properties, and inhibition by antifolates. *Molecular pharmacology* 1969; 5: 49-59.
- Fidock DA, Nomura T, Talley AK, *et al.* Mutations in the *P. falciparum* digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. *Molecular cell* 2000; 6: 861-71.
- Foote SJ and Cowman AF. The mode of action and the mechanism of resistance to antimalarial drugs. *Acta tropica* 1994; 56: 157-71.
- Garavelli PL and Corti E. Chloroquine resistance in *Plasmodium vivax*: the first case in Brazil. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 1992; 86: 128.

- Garg M, Gopinathan N, Bodhe P and Kshirsagar NA. Vivax malaria resistant to chloroquine: case reports from Bombay. Transactions of the Royal Society of Tropical Medicine and Hygiene 1995; 89: 656-7.
- Gregson A and Plowe CV. Mechanisms of resistance of malaria parasites to antifolates. Pharmacological reviews 2005; 57: 117-45.
- Guerra CA, Snow RW and Hay SI. Mapping the global extent of malaria in 2005. Trends in parasitology 2006; 22: 353-8.
- Harinasuta T, Suntharasamai P and Viravan C. Chloroquine-resistant falciparum malaria in Thailand. Lancet 1965; 2: 657-60.
- Hastings MD, Maguire JD, Bangs MJ, *et al.* Novel *Plasmodium vivax* dhfr alleles from the Indonesian Archipelago and Papua New Guinea: association with pyrimethamine resistance determined by a *Saccharomyces cerevisiae* expression system. Antimicrobial agents and chemotherapy 2005; 49: 733-40.
- Hastings MD, Porter KM, Maguire JD, *et al.* Dihydrofolate reductase mutations in *Plasmodium vivax* from Indonesia and therapeutic response to sulfadoxine plus pyrimethamine. The Journal of infectious diseases 2004; 189: 744-50.
- Hastings MD and Sibley CH. Pyrimethamine and WR99210 exert opposing selection on dihydrofolate reductase from *Plasmodium vivax*. Proceedings of the National Academy of Sciences of the United States of America 2002; 99: 13137-41.
- Hawkins VN, Joshi H, Rungsihirunrat K, Na-Bangchang K and Sibley CH. Antifolates can have a role in the treatment of *Plasmodium vivax*. Trends in parasitology 2007; 23: 213-22.
- Health MoP. Malaria Control Program in Thailand. Malaria Control Program in Thailand 2003;
- Herrera S, Perlaza BL, Bonelo A and Arevalo-Herrera M. Aotus monkeys: their great value for anti-malaria vaccines and drug testing. International journal for parasitology 2002; 32: 1625-35.
- Huang T, Barclay BJ, Kalman TI, von Borstel RC and Hastings PJ. The phenotype of a dihydrofolate reductase mutant of *Saccharomyces cerevisiae*. Gene 1992; 121: 167-71.

- Hurwitz ES, Johnson D and Campbell CC. Resistance of *Plasmodium falciparum* malaria to sulfadoxine-pyrimethamine ('Fansidar') in a refugee camp in Thailand. *Lancet* 1981; 1: 1068-70.
- Hyde JE. The dihydrofolate reductase-thymidylate synthetase gene in the drug resistance of malaria parasites. *Pharmacology & therapeutics* 1990; 48: 45-59.
- Hyde JE. Drug-resistant malaria. *Trends in parasitology* 2005; 21: 494-8.
- Hyde JE. Mechanisms of resistance of *Plasmodium falciparum* to antimalarial drugs. *Microbes and infection / Institut Pasteur* 2002; 4: 165-74.
- Imwong M, Pukrittakayamee S, Looareesuwan S, *et al.* Association of genetic mutations in *Plasmodium vivax dhfr* with resistance to sulfadoxine-pyrimethamine: geographical and clinical correlates. *Antimicrobial agents and chemotherapy* 2001; 45: 3122-7.
- Imwong M, Pukrittakayamee S, Looareesuwan S, *et al.* *Plasmodium vivax*: polymerase chain reaction amplification artifacts limit the suitability of *pvgam1* as a genetic marker. *Experimental parasitology* 2001; 99: 175-9.
- Imwong M, Pukrittayakamee S, Cheng Q, *et al.* Limited polymorphism in the dihydropteroate synthetase gene (*dhps*) of *Plasmodium vivax* isolates from Thailand. *Antimicrobial agents and chemotherapy* 2005; 49: 4393-5.
- Imwong M, Pukrittayakamee S, Renia L, *et al.* Novel point mutations in the dihydrofolate reductase gene of *Plasmodium vivax*: evidence for sequential selection by drug pressure. *Antimicrobial agents and chemotherapy* 2003; 47: 1514-21.
- Iyer JK, Milhous WK, Cortese JF, Kublin JG and Plowe CV. *Plasmodium falciparum* cross-resistance between trimethoprim and pyrimethamine. *Lancet* 2001; 358: 1066-7.
- Jelinek T, Ronn AM, Lemnge MM, *et al.* Polymorphisms in the dihydrofolate reductase (DHFR) and dihydropteroate synthetase (DHPS) genes of *Plasmodium falciparum* and *in vivo* resistance to sulphadoxine/pyrimethamine in isolates from Tanzania. *Trop Med Int Health* 1998; 3: 605-9.

- Kaur S, Prajapati SK, Kalyanaraman K, Mohammed A, Joshi H and Chauhan VS. *Plasmodium vivax* dihydrofolate reductase point mutations from the Indian subcontinent. *Acta tropica* 2006; 97: 174-80.
- Kocken CH, van der Wel A, Arbe-Barnes S, *et al.* *Plasmodium vivax*: *in vitro* susceptibility of blood stages to synthetic trioxolane compounds and the diamidine DB75. *Experimental parasitology* 2006; 113: 197-200.
- Konchom S, Singhasivanon P, Kaewkungwal J, *et al.* Trend of malaria incidence in highly endemic provinces along the Thai borders, 1991-2001. *The Southeast Asian journal of tropical medicine and public health* 2003; 34: 486-94.
- Kongsaeree P, Khongsuk P, Leartsakulpanich U, *et al.* Crystal structure of dihydrofolate reductase from *Plasmodium vivax*: pyrimethamine displacement linked with mutation-induced resistance. *Proceedings of the National Academy of Sciences of the United States of America* 2005; 102: 13046-51.
- Korsinczky M, Fischer K, Chen N, Baker J, Rieckmann K and Cheng Q. Sulfadoxine resistance in *Plasmodium vivax* is associated with a specific amino acid in dihydropteroate synthase at the putative sulfadoxine-binding site. *Antimicrobial agents and chemotherapy* 2004; 48: 2214-22.
- Kosaisavee V, Suwanarusk R, Nosten F, *et al.* *Plasmodium vivax*: isotopic, PicoGreen, and microscopic assays for measuring chloroquine sensitivity in fresh and cryopreserved isolates. *Experimental parasitology* 2006; 114: 34-9.
- Krotoski WA, Collins WE, Bray RS, *et al.* Demonstration of hypnozoites in sporozoite-transmitted *Plasmodium vivax* infection. *The American journal of tropical medicine and hygiene* 1982; 31: 1291-3.
- Krungskrai J, Webster HK and Yuthavong Y. *De novo* and salvage biosynthesis of pteroylpentaglutamates in the human malaria parasite, *Plasmodium falciparum*. *Molecular and biochemical parasitology* 1989; 32: 25-37.
- Kublin JG, Witzig RS, Shankar AH, *et al.* Molecular assays for surveillance of antifolate-resistant malaria. *Lancet* 1998; 351: 1629-30.

- Learatsakulpanich U, Imwong M, Pukrittayakamee S, *et al.* Molecular characterization of dihydrofolate reductase in relation to antifolate resistance in *Plasmodium vivax*. *Molecular and biochemical parasitology* 2002; 119: 63-73.
- Leclerc MC, Menegon M, Cligny A, *et al.* Genetic diversity of *Plasmodium vivax* isolates from Azerbaijan. *Malaria journal* 2004; 3: 40.
- Lemcke T, Christensen IT and Jorgensen FS. Towards an understanding of drug resistance in malaria: three-dimensional structure of *Plasmodium falciparum* dihydrofolate reductase by homology building. *Bioorganic & medicinal chemistry* 1999; 7: 1003-11.
- Leslie T, Mayan MI, Hasan MA, *et al.* Sulfadoxine-pyrimethamine, chlorproguanil-dapsone, or chloroquine for the treatment of *Plasmodium vivax* malaria in Afghanistan and Pakistan: a randomized controlled trial. *Jama* 2007; 297: 2201-9.
- Looareesuwan S, White NJ, Chittamas S, Bunnag D and Harinasuta T. High rate of *Plasmodium vivax* relapse following treatment of falciparum malaria in Thailand. *Lancet* 1987; 2: 1052-5.
- Makler MT, Ries JM, Williams JA, *et al.* Parasite lactate dehydrogenase as an assay for *Plasmodium falciparum* drug sensitivity. *The American journal of tropical medicine and hygiene* 1993; 48: 739-41.
- Marlar T, Myat Phone K, Aye Yu S, Khaing Khaing G, Ma S and Myint O. Development of resistance to chloroquine by *Plasmodium vivax* in Myanmar. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 1995; 89: 307-8.
- Martin DC and Arnold JD. Trimethoprim and sulfalene therapy of *Plasmodium vivax*. *The Journal of clinical pharmacology and the journal of new drugs* 1969; 9: 155-9.
- Mayxay M, Pukritrayakamee S, Chotivanich K, Imwong M, Looareesuwan S and White NJ. Identification of cryptic coinfection with *Plasmodium falciparum* in patients presenting with vivax malaria. *The American journal of tropical medicine and hygiene* 2001; 65: 588-92.
- Mayxay M, Pukrittayakamee S, Newton PN and White NJ. Mixed-species malaria infections in humans. *Trends in parasitology* 2004; 20: 233-40.



- Mberu EK, Mosobo MK, Nzila AM, Kokwaro GO, Sibley CH and Watkins WM. The changing in vitro susceptibility pattern to pyrimethamine/sulfadoxine in *Plasmodium falciparum* field isolates from Kilifi, Kenya. *The American journal of tropical medicine and hygiene* 2000; 62: 396-401.
- Mberu EK, Nzila AM, Nduati E, *et al.* *Plasmodium falciparum*: in vitro activity of sulfadoxine and dapsone in field isolates from Kenya: point mutations in dihydropteroate synthase may not be the only determinants in sulfa resistance. *Experimental parasitology* 2002; 101: 90-6.
- McKie JH, Douglas KT, Chan C, *et al.* Rational drug design approach for overcoming drug resistance: application to pyrimethamine resistance in malaria. *Journal of medicinal chemistry* 1998; 41: 1367-70.
- Mendis K, Sina BJ, Marchesini P and Carter R. The neglected burden of *Plasmodium vivax* malaria. *The American journal of tropical medicine and hygiene* 2001; 64: 97-106.
- Mendis KN and Carter R. Clinical disease and pathogenesis in malaria. *Parasitology today* (Personal ed 1995; 11: PT11-16.
- Menegon M, Majori G and Severini C. Genetic variations of the *Plasmodium vivax* dihydropteroate synthase gene. *Acta tropica* 2006; 98: 196-9.
- Milhouh WK, Weatherly NF, Bowdre JH and Desjardins RE. *In vitro* activities of and mechanisms of resistance to antifol antimalarial drugs. *Antimicrobial agents and chemotherapy* 1985; 27: 525-30.
- Mutabingwa TK, Maxwell CA, Sia IG, *et al.* A trial of proguanil-dapsone in comparison with sulfadoxine-pyrimethamine for the clearance of *Plasmodium falciparum* infections in Tanzania. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 2001; 95: 433-8.
- Myat Phone K, Myint O, Myint L, Thaw Z, Kyin Hla A and Nwe Nwe Y. Emergence of chloroquine-resistant *Plasmodium vivax* in Myanmar (Burma). *Transactions of the Royal Society of Tropical Medicine and Hygiene* 1993; 87: 687.

- Na BK, Lee HW, Moon SU, *et al.* Genetic variations of the dihydrofolate reductase gene of *Plasmodium vivax* in Mandalay Division, Myanmar. *Parasitology research* 2005; 96: 321-5.
- Noedl H, Faiz MA, Yunus EB, *et al.* Drug-resistant malaria in Bangladesh: an *in vitro* assessment. *The American journal of tropical medicine and hygiene* 2003; 68: 140-2.
- Noedl H, Wernsdorfer WH, Miller RS and Wongsrichanalai C. Histidine-rich protein II: a novel approach to malaria drug sensitivity testing. *Antimicrobial agents and chemotherapy* 2002; 46: 1658-64.
- Nzila-Mounda A, Mberu EK, Sibley CH, Plowe CV, Winstanley PA and Watkins WM. Kenyan *Plasmodium falciparum* field isolates: correlation between pyrimethamine and chlorocycloguanil activity *in vitro* and point mutations in the dihydrofolate reductase domain. *Antimicrobial agents and chemotherapy* 1998; 42: 164-9.
- Peters W. The prevention of antimalarial drug resistance. *Pharmacology & therapeutics* 1990; 47: 499-508.
- Peterson DS, Walliker D and Wellem TE. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in *falciparum* malaria. *Proceedings of the National Academy of Sciences of the United States of America* 1988; 85: 9114-8.
- Phillips EJ, Keystone JS and Kain KC. Failure of combined chloroquine and high-dose primaquine therapy for *Plasmodium vivax* malaria acquired in Guyana, South America. *Clin Infect Dis* 1996; 23: 1171-3.
- Pinichpongse S, Doberstyn EB, Cullen JR, Yisunsri L, Thongsombun Y and Thimasarn K. An evaluation of five regimens for the outpatient therapy of *falciparum* malaria in Thailand 1980-81. *Bulletin of the World Health Organization* 1982; 60: 907-12.
- Plowe CV. Monitoring antimalarial drug resistance: making the most of the tools at hand. *The Journal of experimental biology* 2003; 206: 3745-52.
- Plowe CV, Cortese JF, Djimde A, *et al.* Mutations in *Plasmodium falciparum* dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns

- of pyrimethamine-sulfadoxine use and resistance. *The Journal of infectious diseases* 1997; 176: 1590-6.
- Plowe CV, Kublin JG and Doumbo OK. *P. falciparum* dihydrofolate reductase and dihydropteroate synthase mutations: epidemiology and role in clinical resistance to antifolates. *Drug Resist Updat* 1998; 1: 389-96.
- Prajapati SK, Joshi H, Valecha N, *et al.* Allelic polymorphism in the *Plasmodium vivax* dihydrofolate reductase gene among Indian field isolates. *Clin Microbiol Infect* 2007; 13: 331-4.
- Pukrittayakamee S, Chantira A, Simpson JA, *et al.* Therapeutic responses to different antimalarial drugs in vivax malaria. *Antimicrobial agents and chemotherapy* 2000; 44: 1680-5.
- Pukrittayakamee S, Vanijanonta S, Chantira A, Clemens R and White NJ. Blood stage antimalarial efficacy of primaquine in *Plasmodium vivax* malaria. *The Journal of infectious diseases* 1994; 169: 932-5.
- Rastelli G, Sirawaraporn W, Sompornpisut P, *et al.* Interaction of pyrimethamine, cycloguanil, WR99210 and their analogues with *Plasmodium falciparum* dihydrofolate reductase: structural basis of antifolate resistance. *Bioorganic & medicinal chemistry* 2000; 8: 1117-28.
- Rieckmann KH, Davis DR and Hutton DC. *Plasmodium vivax* resistance to chloroquine? *Lancet* 1989; 2: 1183-4.
- Rieckmann KH, McNamara JV, Frischer H, Stockert TA, Carson PE and Powell RD. Effects of chloroquine, quinine, and cycloguanil upon the maturation of asexual erythrocytic forms of two strains of *Plasmodium falciparum in vitro*. *The American journal of tropical medicine and hygiene* 1968; 17: 661-71.
- Roper C, Pearce R, Nair S, Sharp B, Nosten F and Anderson T. Intercontinental spread of pyrimethamine-resistant malaria. *Science (New York, N.Y)* 2004; 305: 1124.
- Rungsihirunrat K, Na-Bangchang K, Hawkins VN, Mungthin M and Sibley CH. Sensitivity to antifolates and genetic analysis of *Plasmodium vivax* isolates from Thailand. *The American journal of tropical medicine and hygiene* 2007; 76: 1057-65.

- Russell BM, Udomsangpetch R, Rieckmann KH, Kotecka BM, Coleman RE and Sattabongkot J. Simple *in vitro* assay for determining the sensitivity of *Plasmodium vivax* isolates from fresh human blood to antimalarials in areas where *P. vivax* is endemic. *Antimicrobial agents and chemotherapy* 2003; 47: 170-3.
- Sabatinelli G. [The malaria situation in the WHO European region]. *Meditsinskaia parazitologiya i parazitarnye bolezni* 2000; 4-8.
- Sattabongkot J, Tsuboi T, Zollner GE, Sirichaisinthop J and Cui L. *Plasmodium vivax* transmission: chances for control? *Trends in parasitology* 2004; 20: 192-8.
- Schousboe ML, Rajakaruna RS, Salanti A, *et al.* Island-wide diversity in single nucleotide polymorphisms of the *Plasmodium vivax* dihydrofolate reductase and dihydropteroate synthetase genes in Sri Lanka. *Malaria journal* 2007; 6: 28.
- Schuurkamp GJ, Spicer PE, Kereu RK, Bulungol PK and Rieckmann KH. Chloroquine-resistant *Plasmodium vivax* in Papua New Guinea. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 1992; 86: 121-2.
- Schwartz IK, Lackritz EM and Patchen LC. Chloroquine-resistant *Plasmodium vivax* from Indonesia. *The New England journal of medicine* 1991; 324: 927.
- Sharma VP. Current scenario of malaria in India. *Parassitologia* 1999; 41: 349-53.
- Sibley CH, Brophy VH, Cheesman S, *et al.* Yeast as a model system to study drugs effective against apicomplexan proteins. *Methods* (San Diego, Calif 1997; 13: 190-207.
- Sibley CH, Hyde JE, Sims PF, *et al.* Pyrimethamine-sulfadoxine resistance in *Plasmodium falciparum*: what next? *Trends in parasitology* 2001; 17: 582-8.
- Sidhu AB, Verdier-Pinard D and Fidock DA. Chloroquine resistance in *Plasmodium falciparum* malaria parasites conferred by *pfprt* mutations. *Science* (New York, N.Y 2002; 298: 210-3.
- Sikorski RS and Hieter P. A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in *Saccharomyces cerevisiae*. *Genetics* 1989; 122: 19-27.
- Sirawaraporn W, Sathitkul T, Sirawaraporn R, Yuthavong Y and Santi DV. Antifolate-resistant mutants of *Plasmodium falciparum* dihydrofolate reductase. *Proceedings*

- of the National Academy of Sciences of the United States of America 1997; 94: 1124-9.
- Sirawaraporn W and Yuthavong Y. Kinetic and molecular properties of dihydrofolate reductase from pyrimethamine-sensitive and pyrimethamine-resistant *Plasmodium chabaudi*. *Molecular and biochemical parasitology* 1984; 10: 355-67.
- Sleigh AC, Liu XL, Jackson S, Li P and Shang LY. Resurgence of vivax malaria in Henan Province, China. *Bulletin of the World Health Organization* 1998; 76: 265-70.
- Snounou G and White NJ. The co-existence of Plasmodium: sidelights from falciparum and vivax malaria in Thailand. *Trends in parasitology* 2004; 20: 333-9.
- Snow RW, Guerra CA, Noor AM, Myint HY and Hay SI. The global distribution of clinical episodes of *Plasmodium falciparum* malaria. *Nature* 2005; 434: 214-7.
- Somboon P, Aramrattana A, Lines J and Webber R. Entomological and epidemiological investigations of malaria transmission in relation to population movements in forest areas of north-west Thailand. *The Southeast Asian journal of tropical medicine and public health* 1998; 29: 3-9.
- Sornmani S, Butraporn P, Fungladda W, Okanurak K and Dissapongsa S. Migration and disease problems: a study of pattern of migration in an endemic area of malaria in Thailand. *The Southeast Asian journal of tropical medicine and public health* 1983; 14: 64-8.
- Soto J, Toledo J, Gutierrez P, *et al.* *Plasmodium vivax* clinically resistant to chloroquine in Colombia. *The American journal of tropical medicine and hygiene* 2001; 65: 90-3.
- Tahar R, de Pecoulas PE, Basco LK, Chiadmi M and Mazabraud A. Kinetic properties of dihydrofolate reductase from wild-type and mutant *Plasmodium vivax* expressed in *Escherichia coli*. *Molecular and biochemical parasitology* 2001; 113: 241-9.
- Tahar R, de Pecoulas PE, Mazabraud A and Basco LK. *Plasmodium vivax*: rapid detection by polymerase chain reaction and restriction fragment length polymorphism of the key mutation in dihydrofolate reductase-thymidylate

- synthase gene associated with pyrimethamine resistance. *Experimental parasitology* 1998; 89: 343-6.
- Tasanor O, Noedl H, Na-Bangchang K, Congpuong K, Sirichaisinthop J and Wernsdorfer WH. An *in vitro* system for assessing the sensitivity of *Plasmodium vivax* to chloroquine. *Acta tropica* 2002; 83: 49-61.
- Tasanor O, Ruengweerayut R, Sirichaisinthop J, Congpuong K, Wernsdorfer WH and Na-Bangchang K. Clinical-parasitological response and *in-vitro* sensitivity of *Plasmodium vivax* to chloroquine and quinine on the western border of Thailand. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 2006; 100: 410-8.
- Thimasarn K. Malaria Control Program in Thailand. Malaria Division, Department of Communicable Disease Control, Ministry of Public Health, Thailand. 1999; 88-102.
- Thimasarn K, Sirichaisinthop J, Vijaykadga S, *et al.* *In vivo* study of the response of *Plasmodium falciparum* to standard mefloquine/sulfadoxine/pyrimethamine (MSP) treatment among gem miners returning from Cambodia. *The Southeast Asian journal of tropical medicine and public health* 1995; 26: 204-12.
- Tjitra E, Baker J, Suprianto S, Cheng Q and Anstey NM. Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to *Plasmodium vivax dhfr* mutations. *Antimicrobial agents and chemotherapy* 2002; 46: 3947-53.
- Triglia T and Cowman AF. The mechanism of resistance to sulfa drugs in *Plasmodium falciparum*. *Drug Resist Updat* 1999; 2: 15-9.
- Triglia T and Cowman AF. Primary structure and expression of the dihydropteroate synthetase gene of *Plasmodium falciparum*. *Proceedings of the National Academy of Sciences of the United States of America* 1994; 91: 7149-53.
- Triglia T, Menting JG, Wilson C and Cowman AF. Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in *Plasmodium falciparum*. *Proceedings of the National Academy of Sciences of the United States of America* 1997; 94: 13944-9.

- Triglia T, Wang P, Sims PF, Hyde JE and Cowman AF. Allelic exchange at the endogenous genomic locus in *Plasmodium falciparum* proves the role of dihydropteroate synthase in sulfadoxine-resistant malaria. *The EMBO journal* 1998; 17: 3807-15.
- Valecha N, Joshi H, Eapen A, *et al.* Therapeutic efficacy of chloroquine in *Plasmodium vivax* from areas with different epidemiological patterns in India and their *Pvdhfr* gene mutation pattern. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 2006; 100: 831-7.
- Wang P, Brobey RK, Horii T, Sims PF and Hyde JE. Utilization of exogenous folate in the human malaria parasite *Plasmodium falciparum* and its critical role in antifolate drug synergy. *Molecular microbiology* 1999; 32: 1254-62.
- Wang P, Read M, Sims PF and Hyde JE. Sulfadoxine resistance in the human malaria parasite *Plasmodium falciparum* is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization. *Molecular microbiology* 1997; 23: 979-86.
- Watkins WM, Sixsmith DG, Chulay JD and Spencer HC. Antagonism of sulfadoxine and pyrimethamine antimalarial activity *in vitro* by *p*-aminobenzoic acid, *p*-aminobenzoylglutamic acid and folic acid. *Molecular and biochemical parasitology* 1985; 14: 55-61.
- Wellems TE and Plowe CV. Chloroquine-resistant malaria. *The Journal of infectious diseases* 2001; 184: 770-6.
- Wernsdorfer WH and Payne D. The dynamics of drug resistance in *Plasmodium falciparum*. *Pharmacology & therapeutics* 1991; 50: 95-121.
- Whitby M, Wood G, Veenendaal JR and Rieckmann K. Chloroquine-resistant *Plasmodium vivax*. *Lancet* 1989; 2: 1395.
- White NJ. Antimalarial drug resistance. *The Journal of clinical investigation* 2004; 113: 1084-92.
- White NJ. The assessment of antimalarial drug efficacy. *Trends in parasitology* 2002; 18: 458-64.

- White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs *in vivo*. *Antimicrobial agents and chemotherapy* 1997; 41: 1413-22.
- White NJ and Olliaro PL. Strategies for the prevention of antimalarial drug resistance: rationale for combination chemotherapy for malaria. *Parasitology today (Personal ed)* 1996; 12: 399-401.
- WHO. Chemotherapy of malaria: report of a WHO scientific group. WHO Technical Report Series 1967; 375: 42.
- WHO. World malaria report 2005. WHO document 2005;
- WHO. World malaria situation, 1988. Division of Control of Tropical Diseases. *World health statistics quarterly* 1990; 43: 68-79.
- Wijesekera SK, Carter R, Rathnayaka L and Mendis KN. A malaria parasite toxin associated with *Plasmodium vivax* paroxysms. *Clinical and experimental immunology* 1996; 104: 221-7.
- Winstanley PA. Chemotherapy for falciparum malaria: the armoury, the problems and the prospects. *Parasitology today (Personal ed)* 2000; 16: 146-53.
- Winstanley PA, Mberu EK, Szwandt IS, Breckenridge AM and Watkins WM. *In vitro* activities of novel antifolate drug combinations against *Plasmodium falciparum* and human granulocyte CFUs. *Antimicrobial agents and chemotherapy* 1995; 39: 948-52.
- Wooden JM, Hartwell LH, Vasquez B and Sibley CH. Analysis in yeast of antimalaria drugs that target the dihydrofolate reductase of *Plasmodium falciparum*. *Molecular and biochemical parasitology* 1997; 85: 25-40.
- Wootton JC, Feng X, Ferdig MT, *et al.* Genetic diversity and chloroquine selective sweeps in *Plasmodium falciparum*. *Nature* 2002; 418: 320-3.
- Wu Y, Kirkman LA and Wellems TE. Transformation of *Plasmodium falciparum* malaria parasites by homologous integration of plasmids that confer resistance to pyrimethamine. *Proceedings of the National Academy of Sciences of the United States of America* 1996; 93: 1130-4.
- Yuthavong Y. Basis for antifolate action and resistance in malaria. *Microbes and infection / Institut Pasteur* 2002; 4: 175-82.



Yuvaniyama J, Chitnumsub P, Kamchonwongpaisan S, *et al.* Insights into antifolate resistance from malarial DHFR-TS structures. *Nature structural biology* 2003; 10: 357-65.

Zolg JW, Plitt JR, Chen GX and Palmer S. Point mutations in the dihydrofolate reductase-thymidylate synthase gene as the molecular basis for pyrimethamine resistance in *Plasmodium falciparum*. *Molecular and biochemical parasitology* 1989; 36: 253-62.

